GSK (GSK)
Company Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
It operates through two segments, Commercial Operations and Total R&D.
The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines.
It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.
The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.
GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

Country | UK |
IPO Date | Mar 28, 1980 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 68,629 |
CEO | Emma Natasha Walmsley |
Contact Details
Address: 980 Great West Road Brentford, UK | |
Website | https://www.gsk.com |
Stock Details
Ticker Symbol | GSK |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001131399 |
CUSIP Number | 37733W204 |
ISIN Number | US37733W2044 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Emma Natasha Walmsley | Chief Executive Officer & Director |
Sally Jackson | Senior Vice President of Global Communications & Chief Executive Officer Office |
Diana Conrad | Chief People Officer |
Julie Belita Brown A.C.A. | Chief Financial Officer & Executive Director |
David Simon Redfern BSc (Hons), CA | President of Corporate Development |
James Ford | Senior Vice President & Group General Counsel of Legal & Compliance |
Nick Stone | SVice President & Head of Investor Relations |
Philip C. Thomson | President of Global Affairs |
Shobie Ramakrishnan | Chief Digital & Technology Officer |
Tony Wood | Chief Scientific Officer and Head of R&D |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 28, 2025 | 6-K | Filing |
Feb 27, 2025 | 6-K | Filing |
Feb 27, 2025 | 6-K | Filing |
Feb 26, 2025 | 6-K | Filing |
Feb 26, 2025 | 6-K | Filing |
Feb 25, 2025 | 6-K | Filing |
Feb 24, 2025 | 6-K | Filing |
Feb 24, 2025 | 6-K | Filing |
Feb 21, 2025 | 6-K | Filing |
Feb 21, 2025 | 6-K | Filing |